FDA Clears Cosentyx for Polymyalgia Rheumatica, Roche's Wilserdly for ESR1-Mutated Breast Cancer
FDA approved Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica and Roche's Wilserdly after a 62% risk reduction, while Gilead licensed obeldesivir across 127 countries.
TAG K-7275 · 566 words on the filing

Summary of findings
- FDA approved Cosentyx (secukinumab) as the first anti-IL-17 biologic for polymyalgia rheumatica based on the Phase III Replenish trial.
- Up to 40% of polymyalgia rheumatica patients relapse on steroids within a year.
- FDA approved Roche's Wilserdly plus everolimus after the Phase III EvERA trial showed a 62% reduction in risk of progression or death.
- Gilead signed royalty-free obeldesivir licenses with Dr. Reddy's, Eva Pharma and Ferozsons Laboratories covering 127 countries ahead of Ebo-pep Phase III results.
Two FDA approvals landed this week: Novartis's Cosentyx became the first and only anti-IL-17 biologic cleared for polymyalgia rheumatica, and Roche's Wilserdly won approval for ESR1-mutated advanced breast cancer. The same week, Gilead Sciences signed royalty-free licensing deals for its investigational Ebola antiviral across 127 countries.
The decisions widen treatment options in rheumatology and oncology, but each carries caveats worth weighing before the commercial forecasts move.
What did the Cosentyx approval show?
FDA approved Cosentyx (secukinumab) for polymyalgia rheumatica, a disease where up to 40% of patients relapse on steroids within a year. The approval rests on the Phase III Replenish trial, which showed secukinumab doubled the likelihood of sustained remission.
The claim to watch: "first and only anti-IL-17 biologic" is a class distinction, not a demonstration of superiority over existing steroid-sparing options. Novartis did not release the trial's absolute remission figures in the announcement.
Why Wilserdly matters in breast cancer
FDA also approved Roche's Wilserdly in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer.
The Phase III EvERA trial showed a 62% reduction in the risk of progression or death versus standard therapy. That is a large effect size for this setting, though the announcement did not specify median progression-free survival or the comparator regimen in detail. ESR1 mutations mark a patient population with limited targeted options after prior endocrine therapy.
What is Gilead doing with obeldesivir?
Gilead signed royalty-free voluntary licensing agreements with Dr. Reddy's Laboratories, Eva Pharma, and Ferozsons Laboratories to manufacture and supply obeldesivir. The investigational antiviral is under study as post-exposure prophylaxis for Ebola Bundibugyo virus disease.
The deals cover 127 mostly low- and lower-middle-income countries, including every African nation that has reported cases in the current outbreak. They are modeled on Gilead's earlier remdesivir Covid-19 licenses.
The timing matters. Gilead is building manufacturing and supply capacity ahead of results from the Ebo-pep trial, a partner-led Phase III field study. Obeldesivir remains investigational; the licenses promise access only if the data hold up.
Jaime McCoy, vice president of Gilead Patient Solutions, said the agreements reflect the company's commitment to "preparing for future access while clinical research is ongoing."
That phrasing concedes the central uncertainty. No efficacy readout exists yet, and field trials in outbreak settings have a history of missing enrollment targets.
Is agentic AI more than a productivity story?
Pharmaceutical Executive also spoke with Ankit Jain, chief executive officer and founder of Infinitus, on how agentic AI models are reshaping pharma's commercial operations.
Jain argues the technology needs to drive broader industry change rather than just productivity gains. He points to agents that log CRM data and prep field reps during drive time. He also cites always-available virtual reps that can answer physician questions around the clock instead of only during scheduled sales visits.
The claim is plausible on cost. Whether it changes commercial models or merely trims them is the question buyers should ask before signing.
What to watch next
- Ebo-pep Phase III results, which will determine whether the 127-country licensing architecture has a product to deliver.
- Uptake of Cosentyx in polymyalgia rheumatica, a market where steroids remain the entrenched default.
- Wilserdly launch metrics in the ESR1-mutated segment, where companion-diagnostic gating will shape the addressable population.
via FDA industry wire (Google News) (Source)
More from Rebecca Stone
Show full bio
Staff writer covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.
10 articles
Linked filings
- K-8685
- K-4971
- P-6323
- C-4460
- V-7932